21st Dec 2015 14:47
Director Declaration
LONDON, UK, 21 December 2015 - Skyepharma PLC (LSE SKP), the expert oral and inhalation drug development company, today announces that John Biles, a Non-Executive Director of the Company, ceased to be a Non-Executive Director of HellermannTyton Group PLC on 18 December 2015, the date on which the Scheme of Arrangement whereby HellermannTyton Group PLC was taken over by Delphi Automative PLC became effective.
This information is disclosed to the London Stock Exchange in accordance with the requirements under paragraph 9.6.14R of the United Kingdom Listing Rules relating to the disclosure of changes in the existing directorships in publically quoted companies by a Director of the Company.
For further information please contact:
Skyepharma PLC | |
Peter Grant, Chief Executive Officer Andrew Derodra, Chief Financial Officer | +44 (0)20 7881 0524 |
Jonathan Birt, Investor and Media Relations | +44 (0)7860 361746 |
About Skyepharma PLC
Skyepharma combines proven scientific expertise with validated proprietary technologies to develop innovative oral and inhalation pharmaceutical products. The Group's licenses cover 16 approved inhalation, oral, topical and injectable products, which generate milestones, recurring royalties, and in some cases, product supply revenues. The Group also earns milestones and contract development revenues from new product developments. Products developed by Skyepharma are marketed by some of the world's most respected pharmaceutical companies. For more information, visit www.skyepharma.com.
Related Shares:
SKP.L